Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

1. Influenza communication guide: How to increase influenza vaccination uptake and promote preventive measures to limit its spread

Influenza communication guide: How to increase influenza vaccination uptake and promote preventive measures to limit its spread Influenza seasonal Communication toolkit guidelines Influenza Communication toolkit guidelines 1. Target audience 1 2. How this toolkit can help you 1 2.1 What’s in the toolkit? 2 Types of materials 2 Logo/pins 2 Posters 2 Factsheets 2 Leaflets 2 Web banners 2 2.2 How to use the toolkit 3 Graphics 3 Fonts 3 2.3 Using the tools effectively 3 3. Targeted information (...) Communication toolkit guidelines 1 These guidelines present the ECDC influenza communication toolkit, designed to help European health authorities and organisations to devise communication activities to tackle seasonal influenza. If you are involved in influenza communication programmes or are planning to organise communication activities on influenza prevention, these guidelines can be a helpful resource. This guidelines aim to provide support for: • He alth c ommu nic ation e xper ts • Influen z a pr ogr

2019 European Centre for Disease Prevention and Control - Technical Guidance

2. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis

Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome.Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, and Web of Science) and trial registries were (...) ). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted odds ratio, 2.74; 95% CI, 1.51-4.95). Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly > 40 mg methylprednisolone [or equivalent] per day).Corticosteroid treatment in influenza

2019 EvidenceUpdates

3. Zanamivir (Dectova) - influenza A or B

Zanamivir (Dectova) - influenza A or B Published 09 December 2019 1 Product update SMC2204 zanamivir 10mg/mL solution for infusion (Dectova®) GlaxoSmithKline 9 August 2019 (Issued 8 November 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission zanamivir (Dectova®) is accepted (...) for use within NHSScotland. Indication under review: Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged = 6 months) when: ? the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or ? other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Zanamivir should be used

2019 Scottish Medicines Consortium

4. Inactivated influenza vaccine: information for healthcare practitioners

Inactivated influenza vaccine: information for healthcare practitioners Inactivated influenza vaccine: information for healthcare practitioners - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Inactivated (...) influenza vaccine: information for healthcare practitioners Guidance for healthcare practitioners about the inactivated influenza vaccine. Published 19 October 2016 Last updated 26 November 2019 — From: Documents Ref: PHE publications gateway number 2019081 . Published 19 October 2016 Last updated 26 November 2019 26 November 2019 Updated antibiotic section and reference to gelatin. 22 October 2019 Revised the guidance to include information on checkpoint inhibitors. 20 August 2019 Added new version

2019 Public Health England

5. Seasonal influenza: managing cases in critical care units

Seasonal influenza: managing cases in critical care units Seasonal influenza: managing cases in critical care units - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Seasonal influenza: managing cases (...) in critical care units Advice and recommendations for healthcare professionals on managing seasonal influenza cases in adult critical care units. Published 28 July 2017 Last updated 22 November 2019 — From: Documents Ref: PHE publications gateway number: GW-902 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details

2019 Public Health England

6. Zanamivir (Dectova) - influenza

Zanamivir (Dectova) - influenza Final Appraisal Recommendation Advice No: 1219 – October 2019 Zanamivir (Dectova ® ) 10 mg/ml solution for infusion Limited submission by GlaxoSmithKline UK This product is not currently marketed in the UK In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4130), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR (...) ) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Zanamivir (Dectova ® ) is recommended as an option for use within NHS Wales for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric

2019 All Wales Medicines Strategy Group

7. Point of care tests for influenza and other respiratory viruses

Point of care tests for influenza and other respiratory viruses Point of care tests for influenza and other respiratory viruses - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote (...) in the General Election on 12 December. Guidance Point of care tests for influenza and other respiratory viruses Support for hospital trusts considering the introduction of point of care testing (POCT) for influenza and other respiratory viruses during winter 2019 to 2020. Published 27 November 2018 Last updated 28 October 2019 — From: Documents Ref: PHE publications gateway number: GW-846 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible

2019 Public Health England

8. Increasing Influenza and Pneumococcal Vaccination Uptake in Seniors Using Point-of-Care Informational Interventions in Primary Care in Singapore: A Pragmatic, Cluster-Randomized Crossover Trial

Increasing Influenza and Pneumococcal Vaccination Uptake in Seniors Using Point-of-Care Informational Interventions in Primary Care in Singapore: A Pragmatic, Cluster-Randomized Crossover Trial Objectives. To evaluate the effectiveness of point-of-care informational interventions in general practitioner clinics to improve influenza and pneumococcal vaccination uptake among elderly patients.Methods. We conducted a pragmatic, cluster-randomized crossover trial in 22 private general practitioner (...) in the intervention and control periods, respectively. Both influenza (5.9% vs 4.8%; P = .047) and pneumococcal (5.7% vs 3.7%; P = .001) vaccination uptake rates were higher during the intervention period compared with the control period. On multilevel logistic regression analysis, follow-up for hypertension, diabetes mellitus, hyperlipidemia, or any combination of the 3 was associated with uptake of both vaccines.Conclusions. Point-of-care informational interventions likely contributed to increased influenza

2019 EvidenceUpdates

9. Vaccine recommendations for children and youth for the 2019/2020 influenza season

Vaccine recommendations for children and youth for the 2019/2020 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth 6 months of age and older. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2019/2020 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. However, LAIV will not be available in Canada for the 2019/2020 season. Keywords: Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

2019 Canadian Paediatric Society

10. Do Corticosteroids Benefit Patients With Influenza Pneumonia?

Do Corticosteroids Benefit Patients With Influenza Pneumonia? Do Corticosteroids Benefit Patients With Influenza Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Do Corticosteroids Benefit Patients With Influenza Pneumonia? x Michael Gottlieb , MD (EBEM Commentator) , x Thomas Seagraves , MD (EBEM (...) Commentator) , x Stephen R. Gore , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: Publication History Published online: July 23, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Among patients with influenza pneumonia, corticosteroids are associated with increased mortality, longer length of stay in the ICU, and higher rates of secondary infection, although there are no data from

2019 Annals of Emergency Medicine Systematic Review Snapshots

11. High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated (...) : January 8, 2019 Project Number: RC1059-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of high dose influenza vaccine in older adults or adults who are immunocompromised? What is the cost-effectiveness of high dose influenza vaccine in older adults or adults who are immunocompromised? What are the evidence-based guidelines associated with the use of high dose influenza vaccine in older adults or adults

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Recommendations for Prevention and Control of Influenza in Children, 2019–2020

Recommendations for Prevention and Control of Influenza in Children, 2019–2020 Recommendations for Prevention and Control of Influenza in Children, 2019–2020 | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies with the greatest impact (...) on clinical care. Recommendations for Prevention and Control of Influenza in Children, 2019–2020 COMMITTEE ON INFECTIOUS DISEASES Abstract This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2019–2020 season. The American Academy of Pediatrics continues to recommend routine influenza immunization of all children without medical

2019 American Academy of Pediatrics

13. Influenza: treatment and prophylaxis using anti-viral agents

Influenza: treatment and prophylaxis using anti-viral agents Influenza: treatment and prophylaxis using anti-viral agents - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Influenza: treatment and prophylaxis (...) using anti-viral agents Guidance on how to manage influenza (flu) using anti-viral agents. Published 23 January 2014 Last updated 8 October 2019 — From: Documents Ref: PHE publications gateway number: GW-685 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Ref: 2014422 If you use assistive technology

2019 Public Health England

14. Influenza-like illness (ILI): managing outbreaks in schools

Influenza-like illness (ILI): managing outbreaks in schools Influenza-like illness (ILI): managing outbreaks in schools - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Influenza-like illness (ILI): managing (...) outbreaks in schools Guidance for local PHE Centre health protection teams about assessing and managing outbreaks of influenza-like illness in schools. Published 2 October 2018 Last updated 26 September 2019 — From: Documents Ref: PHE publications gateway number: GW-688 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use

2019 Public Health England

15. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. (PubMed)

N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. Clinical studies have been inconclusive about the effectiveness of N95 respirators and medical masks in preventing health care personnel (HCP) from acquiring workplace viral respiratory infections.To compare the effect of N95 respirators vs medical masks for prevention of influenza and other viral respiratory infections among HCP.A cluster randomized pragmatic effectiveness study (...) were randomly assigned to wear medical masks (2668 HCP-seasons) when near patients with respiratory illness.The primary outcome was the incidence of laboratory-confirmed influenza. Secondary outcomes included incidence of acute respiratory illness, laboratory-detected respiratory infections, laboratory-confirmed respiratory illness, and influenzalike illness. Adherence to interventions was assessed.Among 2862 randomized participants (mean [SD] age, 43 [11.5] years; 2369 [82.8%]) women), 2371

2019 JAMA Controlled trial quality: predicted high

16. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. (PubMed)

Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. To determine whether any association exists between exposure to 2009 pandemic H1N1 (pH1N1) influenza vaccination during pregnancy and negative health outcomes in early childhood.Retrospective cohort study.Population based birth registry linked with health administrative databases in the province of Ontario, Canada.All live births from November (...) , incidence rate ratios, and risk ratios for potential confounding.Of 104 249 live births, 31 295 (30%) were exposed to pH1N1 influenza vaccination in utero. No significant associations were found with upper or lower respiratory infections, otitis media, any infectious diseases, neoplasms, sensory disorders, urgent and inpatient health services use, pediatric complex chronic conditions, or mortality. A weak association was observed between prenatal pH1N1 vaccination and increased risk of asthma (adjusted

Full Text available with Trip Pro

2019 BMJ

17. Influenza post exposure prophylaxis and treatment: PGD templates

Influenza post exposure prophylaxis and treatment: PGD templates Influenza post exposure prophylaxis and treatment: PGD templates - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Influenza post exposure prophylaxis and treatment: PGD templates Patient group direction (PGD) templates for post exposure prophylaxis and treatment of flu for adult residents and staff of care homes. Published 12 January 2016 (...) technology you use. Details These patient group direction ( 18 March 2019 Updated 'Oseltamivir' patient group direction (PGD) templates. 23 February 2019 Updated Zanamivir powder treatments for influenza guidance. 27 July 2018 Updated patient group direction (PGD) templates with latest versions. 12 January 2016 First published. Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National Insurance number

2019 Public Health England

18. Risk Assessment of Avian Influenza A(H9N2)

Risk Assessment of Avian Influenza A(H9N2) Risk Assessment of Avian Influenza A(H9N2) - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Risk Assessment of Avian Influenza A(H9N2) Published 20 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information (...) Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/risk-assessment-of-avian-influenza-ah9n2/risk-assessment-of-avian-influenza-ah9n2 1. Epidemiology of A(H9N2) in humans Avian influenza A(H9N2) is a common and geographically widespread disease of birds, which has the ability

2019 Public Health England

19. Avian influenza A(H7N4): risk assessment

Avian influenza A(H7N4): risk assessment Avian influenza A(H7N4): risk assessment - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Avian influenza A(H7N4): risk assessment Updated 16 April 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team (...) , The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/avian-influenza-ah7n4-risk-assessment/avian-influenza-ah7n4-risk-assessment Public Health England’s risk assessment for H7N4 Update 12 April 2019: All risk assessments are reviewed regularly, but are not updated unless there is a significant

2019 Public Health England

20. Health Care Support Workers Administering Inactivated Influenza, Shingles and Pneumococcal Vaccines for Adults and Live Attenuated Influenza Vaccine (LAIV) for Children

Health Care Support Workers Administering Inactivated Influenza, Shingles and Pneumococcal Vaccines for Adults and Live Attenuated Influenza Vaccine (LAIV) for Children CLINICAL PROFESSIONAL RESOURCE Health Care Support Workers Administering Inactivated Influenza, Shingles and Pneumococcal Vaccines for Adults and Live Attenuated Influenza Vaccine (LAIV) for Children RCN guidance Version 3 revised 2019 This RCN document applies in England and Wales in line with the National Minimum Standards (...) (for example, the LAIV) 12 ContentsHEALTH CARE SUPPORT WORKERS ADMINISTERING VACCINES FOR ADULTS AND CHILDREN 4 This publication outlines the Royal College of Nursing’s (RCN) position on health care support workers (HCSW) administering vaccines and the role of health care professionals who support them. This publication applies to specific vaccinations given as part of the routine national schedule. These vaccines are: • the delivery of the influenza, pneumococcal and shingles vaccines given to adults

2019 Royal College of Nursing